Skip to content

Study · Not a test of the peptide alone · 2021

3 results

Do GLP-1 Receptor Agonists Increase the Risk of Breast Cancer? A Systematic Review and Meta-analysis.

Piccoli GF, Mesquita LA, Stein C, Aziz M, Zoldan M, Degobi NAH, Spiazzi BF, Lopes Junior GL, Colpani V, Gerchman F

The Journal of clinical endocrinology and metabolism1 Mar 2021Cited by 69 (Europe PMC)

PMID33248445 (opens in a new tab)DOI10.1210/clinem/dgaa891 (opens in a new tab)PepBankPUB-33248445
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 01HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome

    In adults with excess weight or diabetes, GLP-1 receptor agonist treatment did not change breast cancer risk compared with controls (130 versus 107 cases).

    In plain wordsIn adults with excess weight or diabetes, GLP-1 drugs were not linked to more breast cancer than control treatment.

    Peptide
    Liraglutide
    Outcome
    No significant changeBreast cancer risk
    Study

    n: not reported in source

    Comparator
    Controls
    Outcome group
    Adverse events · Cancer

    Measurements

    RR
    0.98 NA
    breast cancer

    Source sentences

    Summary
    Among 48 267 subjects treated with GLP-1RAs, 130 developed breast cancer compared with 107 of 40 755 controls (relative risk [RR], 0.98; 95% confidence interval [CI], 0.76-1.26).
    2 context sentences
    Summary · context
    Reviewers assessed abstracts and full-text articles for RCTs of GLP-1RAs in adults with excessive weight and/or diabetes and a minimum follow-up of 24 weeks.
    Summary · context
    We included 52 trials, of which 50 reported breast cancer events and 11 reported benign breast neoplasms.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 02HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome

    Subset analyses by follow-up, blinding and type of GLP-1 receptor agonist showed no differences in breast cancer risk.

    In plain wordsBreast cancer risk did not differ across follow-up time, blinding or GLP-1 drug type in adults with excess weight or diabetes.

    Peptide
    Liraglutide
    Outcome
    No significant changeBreast cancer risk by follow-up, blinding and GLP-1RA type
    Study

    n: not reported in source

    Comparator
    Between subsets (follow-up, blinding, GLP-1RA type)
    Outcome group
    Adverse events · Cancer

    Source sentences

    Summary
    Subset analyses according to follow-up, participant/investigator blinding, and type of GLP-1RA did not reveal any differences.
    2 context sentences
    Summary · context
    Reviewers assessed abstracts and full-text articles for RCTs of GLP-1RAs in adults with excessive weight and/or diabetes and a minimum follow-up of 24 weeks.
    Summary · context
    We included 52 trials, of which 50 reported breast cancer events and 11 reported benign breast neoplasms.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 03HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome

    In adults with excess weight or diabetes, the risk of benign breast neoplasms did not differ between GLP-1 receptor agonist and control groups.

    In plain wordsIn adults with excess weight or diabetes, GLP-1 drugs were not linked to more benign breast growths than control treatment.

    Peptide
    Liraglutide
    Outcome
    No significant changeBenign breast neoplasms
    Study

    n: not reported in source

    Comparator
    Controls
    Outcome group
    Adverse events · Cancer

    Measurements

    RR
    0.99 NA
    benign breast neoplasms

    Source sentences

    Summary
    The risk of benign breast neoplasms also did not differ between groups (RR, 0.99; 95% CI, 0.48-2.01).
    2 context sentences
    Summary · context
    Reviewers assessed abstracts and full-text articles for RCTs of GLP-1RAs in adults with excessive weight and/or diabetes and a minimum follow-up of 24 weeks.
    Summary · context
    We included 52 trials, of which 50 reported breast cancer events and 11 reported benign breast neoplasms.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.